Betta Pharmaceuticals Co., Ltd.

300558

CNE100002DD9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
39.11 ^CNY	+0.03%		+7.42%	-24.13%

Apr. 19	Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Jan. 04	C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	CI

Wuhan Healthgen Biotechnology Corp. announced that it has received CNY 464.999997 million in funding from Hangzhou Beijia Investment Management Co., Ltd., Betta Pharmaceuticals Co., Ltd.

April 03, 2022

On April 4, 2022, Wuhan Healthgen Biotechnology Corp. closed the transaction.

Latest news about Betta Pharmaceuticals Co., Ltd.

Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	Jan. 03	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd.	23-07-31	CI
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance	23-07-05	DJ
Betta Pharmaceuticals Gets Nod for Voronib Tablets' Listing	23-06-09	MT
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023	23-06-08	CI
C4 Therapeutics, Betta Pharmaceuticals Sign Deal to Develop, Commercialize CFT8919 in Greater China	23-05-30	MT
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC	23-05-30	CI
C4 Therapeutics, Inc. announced that it expects to receive $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	23-05-29	CI
Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022	23-05-16	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Betta Pharmaceuticals Co., Ltd. Announces Profit Distribution Proposal for 2022	23-04-24	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-23	CI
Betta Pharmaceuticals Gets Nod to Start Clinical Trial of Tumor Drug in China	23-03-14	MT
Betta Pharmaceuticals Co., Ltd. cancelled the transaction announced on June 13, 2022	23-01-09	CI
Betta Pharmaceuticals Co., Ltd. Approves Board Elections	22-12-28	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-24	CI
Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 999.999991 million in funding	22-06-12	CI
Betta Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Payable on 30 May 2022	22-05-23	CI
EyePoint Pharmaceuticals Grants Betta Pharmaceuticals Rights to Commercialize Chronic Eye Disorder Treatment in China	22-05-04	MT
Betta Pharmaceuticals Co., Ltd. Approves 2021 Profit Distribution Plan	22-04-29	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI

Chart Betta Pharmaceuticals Co., Ltd.

Duration

Period

More charts

Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Betta Pharmaceuticals Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

39.11 CNY

Average target price

54.14 CNY

Spread / Average Target

+38.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
BETTA PHARMACEUTICALS CO., LTD.	-24.13%	2.26B
MERCK KGAA	+5.31%	69.91B
KYOWA KIRIN CO. LTD.	+10.97%	9.03B
SK BIOPHARMACEUTICALS CO., LTD.	-17.03%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+37.51%	4.31B
YUHAN CORPORATION	+3.92%	3.88B
INDIVIOR PLC	+18.82%	2.37B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.98B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Betta Pharmaceuticals Co., Ltd.

Equities

300558

CNE100002DD9

Pharmaceuticals

Wuhan Healthgen Biotechnology Corp. announced that it has received CNY 464.999997 million in funding from Hangzhou Beijia Investment Management Co., Ltd., Betta Pharmaceuticals Co., Ltd.

Latest news about Betta Pharmaceuticals Co., Ltd.

Chart Betta Pharmaceuticals Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Betta Pharmaceuticals Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals